The vaccine delivers antigens to HLA-DP–expressing dendritic cells for presentation to CD4+ T cells, which helps activate CD8+ cytotoxic T cells. The resulting CTLs kill tumor cells presenting the vaccine peptides on MHC I via perforin/granzyme or Fas–FasL pathways; HLA-DP–positive APCs are not directly killed.